ArticleInternational journal of molecular sciences2025
Machine Learning Framework for Ovarian Cancer Diagnostics Using Plasma Lipidomics and Metabolomics.
Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- SLC25A12 mitigates mitochondrial dysfunction in myoblast senescence, and alleviates cuproptosis-related changes under copper stress.Biology direct · 2026Article
- Preoperative differentiation of borderline and malignant ovarian tumors using interpretable machine learning.Journal of ovarian research · 2026Article
- Advances in ovarian cancer: biological insights, therapeutic innovations, and future perspectives.Journal of ovarian research · 2025Review
- Leveraging Explainable Automated Machine Learning (AutoML) and Metabolomics for Robust Diagnosis and Pathophysiological Insights in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Ovarian cancer (OC), the third most common gynecologic malignancy, exhibits distinct metabolic alterations that could enable early detection via liquid biopsy. We developed an advanced machine learning pipeline integrating lipidomics (HPLC-MS, positive/negative ion modes) and NMR-based metabolomics to analyze plasma samples from 229 subjects, including 103 serous OC patients, 107 benign cases, and 19 healthy controls. By systematically evaluating feature selection methods and machine learning architectures, we identified optimal biomarker combinations for OC detection. Convolutional Neural Network (CNN) model based on Mann-Whitney-selected features demonstrated strong discriminatory power (81% accuracy) in distinguishing malignant from benign cases, while Extreme Gradient Boosting (XGBoost) combined with Support Vector Machine-Recursive Feature Elimination (SVM-RFE) achieved exceptional performance (96% accuracy) in differentiating benign from control samples. For multiclass classification, XGBoost with Kruskal-Wallis-selected features achieved 77% accuracy, while one-versus-one CNN models utilizing Mann-Whitney-selected features attained 78% accuracy, demonstrating optimal performance among tested approaches. The complementary strengths of deep learning and ensemble methods underscore their potential for tailored diagnostic applications. While clinical implementation requires further standardization, these findings provide both a methodological framework for metabolic biomarker discovery and biological insights into OC pathophysiology, paving the way for integrated multi-omics approaches in gynecologic oncology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.